How much do GLP-1s cost self-funded employers?

GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound — are now among the most requested employee benefits in the US. And the employers feeling the most pressure aren’t Fortune 500s with dedicated pharmacy benefit teams. They’re self-funded companies with 500 to 5,000 employees trying to offer competitive benefits without a runaway pharmacy budget.

The baseline: what employers are actually paying

List prices for GLP-1 medications approved for weight loss run between $900 and $1,400 per month before rebates. After PBM rebates and plan negotiation, real-world employer costs typically land between $600 and $900 per member per month — or $7,200 to $10,800 per employee per year.

For a self-funded employer with 1,000 employees and a conservative 5% obesity-eligible utilization rate, that’s 50 employees on GLP-1s, costing anywhere from $360,000 to $540,000 annually in pharmacy spend alone — before administration, claims processing, or PBM fees.

AssuredPartners analyzed GLP-1 spend across a dataset of over 3.7 million member months and found that total PMPM costs for the top six GLP-1 drugs increased from $1.43 in 2019 to $24.59 in 2024 — a compounded annual growth rate of 77%. That trajectory has not meaningfully slowed.

What’s driving the cost

Three things are putting upward pressure on employer GLP-1 spend.

1. Utilization is rising faster than expected. According to the Business Group on Health’s 2026 Employer Health Care Strategy Survey, 79% of employers are currently seeing increased utilization of obesity medications, with an additional 15% expecting increases. Employers who added GLP-1 coverage in 2023 and 2024 consistently report that actual utilization exceeded their projections.

2. Discontinuation creates a churn problem. Research from Prime Therapeutics shows only 1 in 12 members remain on GLP-1 treatment after three years. When employees stop — due to side effects, cost, or coverage changes — most regain the weight they lost. Some restart the medication. This cycle of initiation, discontinuation, and reinitiation compounds costs over time without producing lasting health outcomes.

3. High-dose escalation inflates costs. Standard GLP-1 protocols titrate patients upward toward the maximum approved dose (2.4 mg/week for semaglutide). Most vendors and PBM-managed programs follow this auto-titration model. The clinical assumption is that higher doses produce better outcomes — but real-world evidence challenges that assumption, particularly when behavioral support is absent.

Why most coverage models make the cost problem worse

Traditional GLP-1 coverage runs through a PBM. The PBM negotiates rebates, manages prior authorization, and controls formulary access. This model was designed for stable, chronic medications — not for a rapidly evolving drug class with high utilization, high discontinuation, and enormous dose variation.

The PBM model creates three specific problems for self-funded employers: rebates obscure true cost; prior authorization without clinical support doesn’t change outcomes; and there is no tapering mechanism built in. Once an employee is on a GLP-1, the default assumption is indefinite coverage at the approved dose.

The actual cost of a smarter model

A behavior-first GLP-1 program that includes structured clinical oversight, 1:1 coaching, and a tapering protocol changes the cost math significantly.

Embla’s program operates at an average dose of 1.08 mg/week — approximately one-third the standard maximum dose of semaglutide. Across 2,694 participants in the TRIM study (64 weeks, published in Diabetes, Obesity and Metabolism), Embla achieved 16.7% average weight loss while 78.5% of participants successfully tapered or ceased GLP-1 medication entirely by the end of the program.

The financial implication is direct. An employee on 1.08 mg/week costs roughly one-third what an employee on 2.4 mg/week costs in drug spend. When 78.5% eventually taper off entirely, the long-term per-employee cost drops further — while health outcomes are preserved through ongoing behavioral coaching. For self-funded employers, that difference can be $4,800 to $7,800 per employee per year in pharmacy savings versus a standard high-dose program.

What should employers budget?

Here’s a simplified framework for estimating GLP-1 budget exposure at 1,000 employees: conservative utilization (3%) runs $216,000–$324,000 annually; moderate (5%) runs $360,000–$540,000; high utilization (8%) runs $576,000–$864,000. These figures assume $600–$900/member/month net cost under a traditional PBM-managed, high-dose model. A treat-to-target, behavior-first program running at lower average doses reduces these figures substantially.

The question isn’t whether to cover GLP-1s

Fewer than one in five employers currently covers GLP-1s for weight loss. But 79% are seeing utilization increase regardless — because employees are accessing these medications through DTC telehealth platforms, compounding pharmacies, or out-of-pocket, and the demand pressure on employers to formalize coverage is intensifying.

The real question is how you cover them. A program that achieves comparable outcomes at lower doses, with a built-in tapering protocol and behavioral foundation, isn’t just clinically better — it’s financially defensible in a way that open-ended PBM coverage is not.

Embla is a fully managed GLP-1 benefit for self-funded employers. No plan integration required. Pricing under $500 PEPM. Live in 7 days. Talk to our team →